Date: 2015-07-30
Type of information: Nomination
Compound:
Company: Biophytis (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On ?July? 30, 2015, Biophytis,?a ?biotech? company ?specialized? in ?the? development? of drug? candidates ?to? treat ?the ?aging ?diseases, announced ?the ?nomination? of ?Philippe? Dupont ?as ?Chief ?Operating? Officer ?in? order? to? better? support? the? company’s? expansion ?plans.
Philippe?Dupont? began ?his? career? within ?the ?pharmaceutical ?group? Lavipharm ?before ?joining? Opodex? Industrie? as ?a pharmacist, purchasing ?manager. ?More ?recently,?he? was ?the ?COO ?of ?Novagali? Pharma? (Santen? group) ?where ?he ?managed? the?marketing?of? the? medical? devices ?and? the? Regulatory? Affairs. Philippe?Dupont? holds? a ?Phd? in? pharmacy?(Paris?XI? University)? completed? by? an? Executive?MBA? from ?ESSEC.
Financial terms:
Latest news:
